Two co-founders.
One mission.
AI meets regulatory science. Our founders bring together deep expertise in generative AI, computational biology, and compliance-by-design — building the next generation of drug discovery for rare oncology.
Leadership.
Every scientific discipline we need is represented in this pair — and every hire we make going forward extends what these two started.
Our values.
Patients first, always
Rare-oncology patients don't have time to wait a decade. Every optimization we make traces back to shortening their path to a therapy.
Copilot, not oracle
Our AI proposes; humans decide. Every gate has a scientist sign-off — the platform's job is to make the right call obvious, not to make it automatically.
Compliance by design
Regulatory readiness isn't a bolt-on. It's baked into every model, every dataset, every experimental record from day one.
Prove it in the pocket
Predictions are cheap. Binding assays aren't. We resource wet-lab validation on everything before we trust it.
Rare-oncology patients need
faster science.
Patient advocacy groups, pharmaceutical partners, and investors — we'd love to hear from you.